Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just had PR on South Korea and now North Korea is shooting missles...
Volume has been a bit low but there have been some good size blocks moving on the ask.
Here's my take on the chart.
From Stock charts 3 mo. chart
RSI is above 50 and not overbought.
Slow Stoch is set up perfectly and holding above 50.
The ADX confirms it along with on balance volumne.
The 50 DMA has crossed 200 DMA.
The true support was not .008 it is more like .0076 the previous 4 highs from Sept 28 to Aug 20.
We are holding the 13 day moving average very well. That is key.
We are good to go unless someone sees something i don't. GLTYA! Builder
First thing that would be helpful is guidance on the contracts as in what does the compnay believe the sales can approach and secondly what is their plan on moving forward with the contracts. That is the PR we need to take this any further. Sales will come and these contracts and partnerships are fantastic. But give us estimate guidance on estimated sales. I own a building company and contracts are great, all be it mine come with sales. But my private equity holders request guidance all the time. JMO.
builder
Nice buy. I bought back at 1.46, 1.75, and 1.71 recently. just accumulating now. Really think this one was hit way to hard. Should climb into high single digits next six months.
GLTYA! builder
Natural Gas is very near $5.
Tomorrow's a far better day i bet... get these earnings started on the positive. YASH where's our PR.
Bet it gets bought up by bigger co. deals are worth something and a big co. knows it.
Anyone still in this one?
More...
The filing says that the company owes $46 million to U.S. Bank National Association, of Boston, $7.8 million to funds associated with Dallas-based investment firm Maverick Capital, $6.6 million to BB Bioventures in South San Francisco, and $5.5 million to medical products giant Abbott Labs, headquartered in Abbott Park, IL, to name its four largest creditors listed in the bankruptcy filing.
Bankruptcy Lawyer
James A. Wright III
Associate
Ropes & Gray
One International Place
Boston, MA 02110-2624
T + 1-617-951-7168
F + 1-617-235-9542
+ 1-617-854-2178 secretary
E-mail
Found this little tid bit...
The downfall of OSCI nearly 3-months ago has triggered a stream of
corporate-restructuring business for Wall Street, an irony that isn't
lost on Mark Shapiro.
As head of the OSCI's restructuring business, it was Shapiro who
helped orchestrate OSCI's North American operations sale to Barclays
Capital, a unit of Barclays PLC (BCS). "And, it's not often a
restructuring team gets called on to restructure its firm," he said.
Also from website. Believe they still own this own.
Ramoplanin
Oscient Pharmaceuticals has conducted clinical trials for Ramoplanin for the treatment of Clostridium difficile-associated disease (CDAD). Ramoplanin has Fast-Track status from the FDA and the Company has received a Special Protocol Assessment from the FDA for the Phase III clinical trial. Based on a strategic decision to concentrate resources on building the commercial business, Oscient has been seeking to out-license, co-develop or sell the rights to Ramoplanin to a partner.
The first page of the banckruptcy filing. Bottom shows assets to liabilities. Waltham, MA-based debtor's petition lists assets of $174 million, debts as $183 million.
http://www.scribd.com/doc/17331966/Oscient-Pharmaceuticals-Chapter-11-Bankruptcy-Petition
Oscient Pharmaceuticals was founded in 1961 and is headquartered in Waltham, Massachusetts.
This company has been around forever. We may get a nice surprise with this one after all.
The United States Trustee has appointed the members of the Official Committee of Unsecured Creditors in the Oscient Pharmaceuticals Corporation bankruptcy case. Oscient Pharmaceuticals filed for bankruptcy protection recently in the District of Massachusetts bankruptcy court.
The members of the Creditors' Committee are:
•U.S. Bank, N.A. (as indenture trustee of 3.5% convertible promissory notes due in 2011)
•Motorlease Corp.
•RxSolutions, Inc.
The representative of U.S. Bank has been appointed as the chairperson of the Creditors' Committee.
http://www.netdocketsblog.com/2009/07/oscient-pharmaceuticals-creditors.html
Think that happened big time today. My condolences. GLTYA! They got there shares.
It's a coin toss. Hope the MM's lost that double headed coin. It's pretty obvious not many people selling but stop orders but not many buying either. I don't really worry about low volumne drops though it is kind of a good thing.
Seems like the vast majority of my little board radar list has been down for the past 4 trading days. Think some are taking a bit off the the table until earnings start in or they are moving it into the big board blue chips. My Smallcap- Midcap stocks have been killing it during the same time. Holding regardless and trying to move some in to make a few buys in the 4's JMO. GLTYA!
10 day chart is impressive. Just started next leg imho. GLTYA! builder
From the PR Aug 4 I think we now share a common board memeber. That has to be a good sign.
BEVERLY HILLS, Calif., Aug 04, 2009 (BUSINESS WIRE) -- Yasheng ECO-Trade Corporation /quotes/comstock/11k!yash (YASH 0.17, -0.01, -5.20%) announced that Eric Qian Wang, PE has been nominated by Yasheng Group (Pink Sheets: YHGG) to be appointed to the Board of Directors of Yasheng ECO-Trade Corporation. Mr. Wang is Director of Engineering for the Yasheng Group. Mr. Wang's appointment will brings the number of the Company directors to six.
I've spent a few hours on this company today. All paper reseasrch but still if this plays out (which the potential is there) this is a large play to say the least. Buy and sell em but i'd accumulate too. hard part is actually verifiing PR's let you all know if i stumble accross the "golden ticket"
sent out for some info from "Golden Dragon", lease in "New" Asia Trade Zone, etc. JMHO! Builder.
Yasheng ECO-Trade Corporation Investor Relations Rosemarie Clamor, 310-461-3559
Office Building
http://maps.google.com/maps?hl=en&tab=wl
2nd tightest bollinger bands I have seen this year. I loved the 1st lets see how this plays out. GLTYA! its about time.
Rather large end of day buy for 1.80 x over 48,000 shares? One hell of a paint job. I'll take it though should have have picked some up earlier at 1.71. Maybe tomorrow... not with my luck.
NEWS! After Hours.
Lupin Expands Branded Play
Tuesday 09/29/2009 4:43 PM ET - Pr Newswire
Related Companies
Symbol Last %Chg
OSCIQ 0.0555 -4.31%
As of 3:42 PM ET 9/29/09
Pharmaceutical Major, Lupin Ltd. announced today the acquisition of US rights for Antara(R) (Fenofibrate Capsules 43 mg and 130 mg). Lupin acquired the product from Oscient Pharmaceuticals on September 25, 2009, under the procedures of the U.S. Bankruptcy Court. Antara recorded net sales of US $ 70 million for 2008 (Source: IMS Dec 2008). Lupin paid $ 38.61 million for the product and related assets inclusive of inventory.
Lupin had previously filed an ANDA for Fenofibrate Capsules 43 mg and 130 mg. On September 21, 2009, prior to the acquisition of Antara(R), Lupin sold its ANDA to Dr. Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product.
Prior to the acquisition, Antara(R) was marketed by Oscient Pharmaceuticals. Antara(R) has a strong brand equity with primary care physicians treating patients for high LDL-C, Total-C, triglycerides, Apo-B and low HDL-C. The Fenofibrate products market is $ 1.9 Billion for the last 12 months. Antara(R) has 4.5% share of this market and grew 20 % in revenue this past year. Antara(R) is prescribed for adjunct treatment of hypercholesterolemia (high blood cholesterol) and hyper-triglyceridemia (high triglycerides) in combination with diet.
The Antara acquisition enables Lupin to enter the primary care market with a three product portfolio. Lupin's Suprax Tabs and Allernaze have strong potential in primary care. Lupin will be more than doubling its sales force size in the next 12 months to reach the key targets for the three products.
"We are very excited with our 2nd NDA acquisition within a span of 4 months. The Antara(R) acquisition demonstrates Lupin's success in, and commitment to building its brand franchise and equity in the US. It underlines Lupin's differentiated strategy for the US market. Antara(R) is a step forward that will help us strengthen and grow our brand business. Since Antara(R) is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our topline and bottomline in the coming quarters and years," said Vinita Gupta, Group President & CEO, Lupin Pharmaceuticals Inc
About Lupin
Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant market share in key markets in the Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.
Our Drugs and products reach over 70 countries in the world. Today, Lupin has the unique distinction of being the fastest growing top 10 Generics player in the two largest pharmaceutical markets of the world -- The U.S. (ranked 9th by prescriptions & growing at 92 %) and Japan (ranked 7th and growing at 23%). The company is also the fastest growing, top 5 pharmaceutical player in India (ORG IMS - March 2009) and the fastest growing Generic player in South Africa (ranked 6th and growing at over 30 % YoY - IMS)
For the financial year ended March 2009, Lupin's Consolidated Revenues and Profit after Tax were Rs. 39,145 million and Rs. 5015 million respectively.
Watch YASH Bollinger Squeeze. Tight
GLTYA! Builder
Thanks. In on that same technical run I see coming as well. Bollinger Band squeezeeeeeeee. Just seen a ton of mergers and buyouts lately. That would sure help. GLTYA! builder
Callon to buy producing assets rather than drill - CEO CALLON/ (INTERVIEW)
Thursday September 24, 2009 02:47:17 AM GMT
http://www.forexyard.com/en/reuters_inner.tpl?action=2009-09-22T174750Z_01_BNG515129_RTRIDST_0_CALLON-INTERVIEW
* Says current gas prices do not support drilling new wells
* Says focus on acquiring onshore properties * Says service costs could come down further
* Says not interested in selling co
By Arup Roychoudhury
BANGALORE, Sept 22 (Reuters) - Oil and natural gas company Callon Petroleum Co will focus on acquiring functional properties rather than drilling new wells given the low natural gas price environment, the company's Chief Executive Rick Callon said.
"At this time it's better to buy producing properties than to drill... There still are a number of good opportunities on the shelf but they don't make sense at $3 gas prices," Callon said by phone.
Drilling would be profitable in the shelf or shallow water Gulf of Mexico (GoM) at a rate above $6, but the timing of natural gas prices reaching that level was still anybody's guess, said the CEO.
The company, which has assets in shallow and deepwater of GoM, will now look to invest in and develop onshore activities, he said.
Callon said he expects gas prices to bounce back to $7-$8 as supply from the shale plays come down and demand picks up over the next 6 to 18 months
Oil prices have doubled from the lows touched earlier this year, while natural gas prices have remained depressed due to weak North American demand and increased production from shale plays due to advances in technology.
Two third of Callon Petroleum's total proved reserves is crude oil and the rest is natural gas.
"Longer term our view is that we would like to have a balance between oil and gas. In the short term like many, we are more bullish on oil prices in terms of oil being in the $70-80 range and recognising that we are going to see fluctuation," said the CEO.
However, Callon said he does not see oil prices going above $90 or falling below $50 in the short term.
Earlier this month Saudi Oil Minister Ali al-Naimi said he was completely happy with the oil price, which was driven by economic growth and was ignoring high levels of inventory as part of a fundamental shift in the market.
COSTS MAY DROP FURTHER
CEO Callon said oilfield services costs could drop further depending on what happened with gas prices.
However, he noted that reduction in service costs till now varied from region to region.
Callon said that day rates for Jackup rigs -- primarily used to drill in shallow waters -- have come down.
"But deepwater component of the offshore tends to keep some offshore costs up because there is enough activity out there," he added.
Lower commodity prices in the first two quarters of the year had brought down the cost of drilling wells, allowing producers to get more for their money.
WONT SELL OUT NOW
The rebound in oil prices has renewed investor interest in energy companies and the Dow Jones U.S. Exploration & Production Index is up 31 percent so far this year.
Last week, Callon Petroleum's peer Parallel Petroleum was acquired by investor Leon Black's buyout firm Apollo Global Management for $483 million, including debt.
However, Callon said he will not consider selling the company for the next several years even if an attractive offer came by.
"For a company our size we have got a lot of opportunity here to grow...I think for the next several years, there is certainly much more upside potential for our shareholders with us remaining independent." (Editing by Jarshad Kakkrakandy) (arup.roychoudhury@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: arup.roychoudhury.reuters.com@reuters.net))
Is this company a canidate for a buyout? Newbie with this one and pharma for that matter. Seems like it could be attractive at the right price. TIA!
I Like this qoute
"Bollinger Bands has closed above bottom band by 36.2%; Bollinger Bands are 88% narrower than normal.The narrow width of the bands suggests low volatility as compared to YASH.OB's normal range. The bands have been in this narrow range for 5 bars. This is often a sign that a market may be about to initiate a new trend."
http://www.allotcbb.com/quote.php?symbol=yash
GLTYA Builder.
Patience my friend. I was actually expecting %10- down on this today. Held up well really. Chart looks better.
Solid Close.
Picked up starter position today. waited for the 200dma to look like it is leveling. Solid base here imo. GLTYA! Builder.
Quiet day around here...
Anyone here? THis thing has been kind over the past few months.
Any day we move from a technical standpoint anyway. Should see some volumn coming in based just on that. THe PR is anyones guess. We shall see.
Looking for bounce off 13dma. Then primed for next leg up.Holding up very nicely. Chart looks good imo.
Anyone have Level 2 on this
Watch this thing move in the next few days. 50dma just crossed 200dma with rising adx. And the political issues with Poland and out missle defense. GLTYA Builder.
So not to rub it in or anything but glad most of us didn't sell at .0007. That would have surely sucked to have gotten home to see this! Great stuff. Can't wait to see how it all plays out. And for what its worth I use closed cell spray foam in absolutly everything possible I build. And in far the South it is even better due to mold. It is the way of the future. They have something here. A notch above the competition. I just hope they work this intelligantly. GLTYA! Builder
There's a little man screaming in my ear "told you not to sell at $8". back in soon enough. have a tall one on me. no... wait.. make that AIB. GLTYA Builder
Planning on picking up some URST myself. Be nice if that little gap fills Monday.;) GLTYA Builder
Thanks for the invite gofor. New to the board. Like my miners and oil. Cheers to a heck of a year. GLTYA Builder
Finally closed above 13d sma. Good sign been waiting for that. Up from here. GLTYA.
This move may have legs. another run like in april. $5 - 3 weeks? Go baby go!